AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03127813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of continuous positive airway pressure (CPAP)
Description: CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order
Study NCT03127813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of continuous positive airway pressure (CPAP)
Description: CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order
Study NCT01287975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Use of conventional manual facilitation and function-based training used in conventional occupational therapy training for post-stroke upper limb weakness.~Training is modelled along the neurodevelopmental techniques and will include stretching, tone management, weight bearing exercises, movement facilitation, selfcare training, arm ergometry by arm bicycles and grip strength training.~Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
Study NCT01287975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI Haptic Knob
Description: BCI based robotic rehabilitation works by detecting the motor intent of the user from electroencephalogram signals to drive the robotic rehabilitation via Haptic Knob. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
Study NCT01287975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic Knob
Description: Haptic Knob is an upper limb robot designed for use in robotic-assisted rehabilitation of the stroke wrist and hand. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
Study NCT00572975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pentadecanoic acid (PA) and Triheptadecanoin (THA)
Description: Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.~in breakfast shake x1
Study NCT04805359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normoxic exercise
Description: Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
Study NCT00887198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo tablets per day taken orally.
Study NCT00887198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg tablet orally twice daily.
Study NCT00887198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: 5 mg tablet orally twice daily.
Study NCT02648711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: infusion CRLX101 weekly
Study NCT02648711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: infusion weekly CRLX101 + bevacizumab biweekly
Study NCT02648711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
Study NCT04513275 — intervention group
Intervention type: DRUG
Intervention: non-medicine intervention
Description: rating by MCCB only one time
Study NCT01754532 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hair Sample
Description: Analysis of hair cortisol levels
Study NCT02048683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short term sedation with sevoflurane in ICU
Study NCT02048683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Short term sedation with sevoflurane in ICU
Study NCT02304562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB Mesenchymal Stem Cells treatment
Description: reduce skin injury
Study NCT01165359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITX 5061
Description: For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.~For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.~For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days.
Study NCT01165359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ITX 5061
Description: For Part A of the study: placebo, once a day for 3 days.~For Part B of the study: placebo, once a day for 14 days.~For Part C of the study: placebo, once a day for 28 days.
Study NCT05684666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow Breathing Exercise (SBE)
Description: Slow Breathing Exercise (SBE) delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to make six breaths per minute for 30 minutes per session, twice a week for 4 weeks.
Study NCT05684666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) Technique
Description: Progressive Muscle Relaxation (PMR) Technique delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to complete all sixteen steps of PMR technique for 30 minutes per session, twice a week for 4 weeks.
Study NCT03330171 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles vaccine
Description: All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.
Study NCT03330171 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis-A vaccine
Description: Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.
Study NCT03330171 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Varicella vaccine
Description: Half of the participants (n=135) will receive varicella vaccine at 18 months of age.
Study NCT01384383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5885
Description: GS-5885 30 mg tablet administered orally once daily
Study NCT01384383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9451
Description: GS-9451 200 mg tablet administered orally once daily
Study NCT01384383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01384383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study NCT04390412 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiotherapy
Description: 0.5 Gy radiation to both lungs in an AP/PA treatment plan
Study NCT01019499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: berry products
Description: effects of berry consumption on cardiovascular indicators~two portions daily
Study NCT01019499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control products
Description: two portions daily
Study NCT04805359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise
Description: Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
Study NCT00555997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
Study NCT00555997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo
Study NCT01239836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constructivist interactive workshop on urinary incontinence
Description: A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.
Study NCT01239836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based self-management tool
Description: Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.
Study NCT01239836 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: General health lecture
Description: Participants will attend a lecture on general women's health issues that does not address urinary incontinence.
Study NCT02358980 — intervention group
Intervention type: DEVICE
Intervention: KIDNEY therapy
Study NCT00003162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pain therapy
Study NCT00003162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain therapy
Study NCT00003162 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT00003162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01580995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir 500 mg po bid
Study NCT01580995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily
Study NCT04278495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cozaar (Losartan Potassium 25mg)
Description: Cozaar (Losartan Potassium 25mg)
Study NCT04278495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04083937 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with photons
Description: hypofractionated radiotherapy with photons (total dose 57.0 Gray in 19 fractions)
Study NCT04083937 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with protons
Description: hypofractionated radiotherapy with protons (total dose 57.0 Gray relative biological effectiveness (RBE) in 19 fractions)
Study NCT04083937 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Normofractionated radiotherapy with photons
Description: normofractionated radiotherapy with photons (total dose 70.0 Gray in 35 fractions)
Study NCT00275301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
Study NCT02361879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: 5 mg/day will be administered starting from day 1 of the cycle and up to three months later
Study NCT02361879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
Study NCT01939210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in breathing training sessions
Study NCT01939210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Participate in breathing training sessions
Study NCT01939210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01939210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00571077 — intervention group
Intervention type: DEVICE
Intervention: Electrical Impedance Scanning (EIS) of the Thyroid gland
Description: Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
Study NCT02137499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko device
Description: Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
Study NCT02137499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: geko device
Description: Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
Study NCT01845649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3011 Estradiol Vaginal Cream
Description: Daily for 14 days followed by 3 times per week for 10 weeks
Study NCT01845649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Daily for 14 days followed by 3 times per week for 10 weeks
Study NCT01310712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 5 mg every 12 hours for 6 weeks
Study NCT01310712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo twice a day for 42 days.
Study NCT00816647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellofemoral stabilizing surgery
Description: Comparison of surgical techniques
Study NCT02151630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyruvic acid
Study NCT01577719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimedia Lifestyle Improvement
Description: * Online Goal setting to improve diet, physical activity or smoking behaviours~* regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.~* Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks.
Study NCT01577719 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
Study NCT01074723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: b-cryptoxanthin and phytosterols
Description: Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
Study NCT02151630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salicylic Acid
Study NCT01984749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed.~1. The starting dose of the investigational product (febuxostat) will be 10 mg/day.~2. The dose will be increased to 20 mg/day at Week 4.~3. The aim is to increase the dose to 40 mg/day at Week 8.
Study NCT04252300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).
Study NCT04252300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin + BAY1817080
Description: A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
Study NCT02288364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine
Study NCT02288364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine plus sodium bicarbonate
Study NCT00513058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d
Study NCT00513058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
Study NCT00349622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years.
Study NCT00349622 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study NCT02151643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT20
Description: Modified ferric oxide adipate tablets
Study NCT01195181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon plus ribavirin
Description: peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
Study NCT04126642 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment only group
Description: Individuals randomized to this group will receive radiation therapy as usual plus baseline, follow-up, and EMA assessments.
Study NCT04126642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Individuals randomized to the intervention group will complete the same measures (in person and daily EMAs) as the assessment only group, but will additionally receive messaging that is tailored to patient responses on EMAs.
Study NCT02384109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making with pharmacists
Description: Pharmacist will engage patient using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change with a goal of 7% weight loss or metformin. Patients interested in lifestyle change will be referred to a CDC (Center for Disease Control and Prevention)-approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
Study NCT02384109 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care from primary care providers
Description: Primary care providers address pre-diabetes as part of usual care, which may involve no action, referrals, or treatment with medications.
Study NCT03040505 — intervention group
Intervention type: OTHER
Intervention: questionnary
Description: Participant's verbalization will be audio recorded and then transcribed by investigators. The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
Study NCT01343992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bed rest
Description: Patients will rest in bed ten minutes after the embryo transfer.
Study NCT01343992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No bedrest
Description: Patients will not rest in bed after the embryo transfer.
Study NCT01861873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: measuring liver function by 18-FDGal PET/CT
Study NCT06531629 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery, radiation therapy and chemotherapy
Description: Surgery, radiation therapy and chemotherapy
Study NCT02151643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to each PT20 dose arm
Study NCT03819751 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI-targeted prostate biopsy
Description: All participants receive traditional cognitive/visual registration biopsy and the above mentioned MRI/TRUS fusion biopsy (also known as software registration biopsy)
Study NCT00460564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1358820
Description: botulinum toxin type A
Study NCT00460564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00460564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01709123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chromium niacinate
Description: 200ug or 500ug supplementation in pill form
Study NCT01709123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pill for chromium niacinate
Study NCT04669002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0057
Description: EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously